Janssen in Rheumatology

[object Object]
Aandachtsgebieden

Introduction Janssen in Rheumatology

The Janssen Medical Cloud section ‘Janssen in rheumatology’, is intended for physicians working in the field of rheumatology, more specifically for the disease of Psoriatic Arthritis. As a loyal partner, we offer you, as a physician, useful information and services within this field.

On our website you will find information about studies, patient materials that you can download, medical education programs, a conference agenda and so much more.

Discover our portfolio

Consult practical information about Janssen's treatment in Rheumatology.

Consult our event calender

Janssen follows the medical news closely and puts together a handy calendar for you with the important events in your field. You will find the current highlights on this page.

See our supporting materials

Download useful patient materials from the Janssen Rheumatology portfolio.

Rheumatology podcast

Rheumatology in 2030: a lively conversation between two Benelux key opion leaders in rheumatology.
Check it out and click here below to get a short flavour of the podcasts.

Rheumatology in 2030. A lively conversation between two Benelux key opinion leaders in rheumatology.

Rheumatology in 2030 part 1:
Technical innovations and improvements benefiting both patients and medical specialists When two distinguished Benelux rheumatologists look ahead to the evolution of their specialty in the next ten years, their optimism is striking. They emphasize the technical innovations and improvements that have recently been implemented, which benefit both the patient and the medical specialist, also on the administrative platform. In a patient-oriented context they will take advantage of digital means, and they can also communicate and share the best expertise in an optimal international network. They will also learn a lot more of what’s really happening in the earliest stages of the disease.
Rheumatology
Rheumatology in 2030 part 2:
Technical innovations and improvements benefiting both patients and medical specialists The role of the rheumatologist is shifting towards that of the expert or the coach in the context of a personalized medicine where shared decisions are taken, in order to find the best treatment. The rheumatology section becomes more and more an outpatient clinic. In an integral network also the voice of the patient will be heard. Communicating in a broader field of work, the rheumatologist gets closer to primary care, aware of healthy food and lifestyle, giving general advice and guiding the patients.
Rheumatology

Rheumatology in 2030 part 1:
Technical innovations and improvements benefiting both patients and medical specialists When two distinguished Benelux rheumatologists look ahead to the evolution of their specialty in the next ten years, their optimism is striking. They emphasize the technical innovations and improvements that have recently been implemented, which benefit both the patient and the medical specialist, also on the administrative platform. In a patient-oriented context they will take advantage of digital means, and they can also communicate and share the best expertise in an optimal international network. They will also learn a lot more of what’s really happening in the earliest stages of the disease.
Rheumatology
Rheumatology in 2030 part 2:
Technical innovations and improvements benefiting both patients and medical specialists The role of the rheumatologist is shifting towards that of the expert or the coach in the context of a personalized medicine where shared decisions are taken, in order to find the best treatment. The rheumatology section becomes more and more an outpatient clinic. In an integral network also the voice of the patient will be heard. Communicating in a broader field of work, the rheumatologist gets closer to primary care, aware of healthy food and lifestyle, giving general advice and guiding the patients.
Rheumatology

News


20 November 2020

European Commission has approved TREMFYA® ▼ (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate
response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.

16 October 2020

Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA® ▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU).

14 July 2020

TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis.

20 October 2019

Janssen Seeks to Expand Use of TREMFYA® ▼ (guselkumab) in the Treatment of Adults with Active Psoriatic Arthritis.

Covid-19 and biologics

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings
Contact us, we're happy to help

Do you have a question for us or did you not find what you were looking for? Let us know and one of our Janssen-specialists will contact you as soon as possible.

Discover our products

Discover Janssen's portfolio and the matching SmPC's.

Look at 3D clinical images

On this page you will find interactive 3D animations of the human anatomy and various syndromes. This allows you to zoom in on the anatomy, tissue structures, disease mechanisms and the course of the disease.